Background The aim of this study was to examine BRF2 expression in patients with non-small cell lung cancer (NSCLC) and explore the relationship of BRF2 protein with clinicopathologic factors, tumor angiogenesis and prognosis. Methods Both BRF2 protein and intratumoral microvessels were examined by immunohistochemical staining in 107 non-small cell lung cancer patients. Intratumoral m icrovessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells. Western blot and RT-PCR analyses were utilized to investigate the BRF2 expression status in tissues Results A notably higher level of BRF2 expression was found in NSCLC tissues at protein levels. In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse. Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021). Conclusions BRF2 is a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy for patients with early-stage NSCLC.
References
[1]
Rooney C, Sethi T (2011) The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration 81: 89–104. doi: 10.1159/000323946
[2]
Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986–3997.
[3]
Ren H, Tang X, Lee JJ, Feng L, Everett DA, et al. (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22: 3230–3237. doi: 10.1200/jco.2004.02.080
[4]
Flehinger BJ, Kimmel M, Melamed MR (1992) The effect of surgical treatment on survival from early lung cancer: implications for screening. Chest 101: 1013–1018. doi: 10.1378/chest.101.4.1013
[5]
Fry WA, Philips JL, Menck HR (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86: 1867–1876. doi: 10.1002/(sici)1097-0142(19991101)86:9<1867::aid-cncr31>3.0.co;2-9
[6]
Crinò L, Weder W, van Meerbeeck J, Felip E (2011) ESMO Guidelines Working Group (2011) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: v103–115. doi: 10.1093/annonc/mdq207
Schramm L, Hernandez N (2002) Recruitment of RNA polymerase III to its target promoters. Genes Dev 16: 2593–2620. doi: 10.1101/gad.1018902
[9]
Wang T, Lv M, Shen S, Zhou S, Wang P, et al. (2012) Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer. PLoS One 7: e43268. doi: 10.1371/journal.pone.0043268
[10]
Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N, et al. (2003) Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell Cycle 2: 181–184. doi: 10.4161/cc.2.3.375
[11]
Johnson SS, Zhang C, Fromm J, Willis IM, Johnson DL (2007) Mammalian Maf1 is a negative regulator of transcription by all three nuclear RNA polymerases. Mol Cell 26: 367–379. doi: 10.1016/j.molcel.2007.03.021
[12]
Reina JH, Azzouz TN, Hernandez N (2006) Maf1, a New Player in the Regulation of Human RNA Polymerase III Transcription. PLoS ONE 1: e134. doi: 10.1371/journal.pone.0000134
[13]
Rollins J, Veras I, Cabarcas S, Willis I, Schramm L (2007) Human Maf1 negatively regulates RNA polymerase III transcription via the TFIIB family members Brf1 and Brf2. Int J Biol Sci 3 (5) 292–302. doi: 10.7150/ijbs.3.292
[14]
Goodfellow SJ, Graham EL, Kantidakis T, Marshall L, Coppins BA, et al. (2008) Regulation of RNA Polymerase III Transcription by Maf1 in Mammalian Cells. J Mol Biol 378 (2) 481–91. doi: 10.1016/j.jmb.2012.12.006
[15]
Jacob J, Cabarcas S, Veras I, Zaveri N, Schramm L (2007) The green tea component EGCG inhibits RNA polymerase III transcription. Biochem Biophys Res Commun 360 (4) 778–783. doi: 10.1016/j.bbrc.2007.06.114
[16]
Cabarcas S, Schramm L (2011) RNA polymerase III transcription in cancer: the BRF2 connection. Molecular Cancer 10 (1) 47–57. doi: 10.1186/1476-4598-10-47
[17]
Lu M, Tian H, Yue W, Li L, Li S, et al. (2013) Overexpression of TFIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer [J]. Medical Oncology 30 (2) 1–9. doi: 10.1007/s12032-013-0553-4
[18]
Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, et al. (2010) Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma. PLoS Med 7 (7) e1000315. doi: 10.1371/journal.pmed.1000315
[19]
Li S-h, Tian H, Yue W-m, Li L, Li W-j, et al. (2011) Overexpression of Metastasis-Associated Protein 1 is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early-Stage Non-Small Cell Lung Cancer. Ann Surg Oncol 18: 2048–2056. doi: 10.1245/s10434-010-1510-5
[20]
Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, et al. (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38: 1564–1579. doi: 10.1016/s0959-8049(02)00094-1
[21]
Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, et al. (2005) The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer. Clinical cancer research 11: 8326–8331. doi: 10.1158/1078-0432.ccr-05-1244
[22]
Geiduschek EP, Kassavetis GA (2001) The RNA polymerase III transcription apparatus. J Mol Biol 310 (1) 1–26. doi: 10.1006/jmbi.2001.4732
[23]
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networksin a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2) 166–80. doi: 10.1593/neo.07112
[24]
Urbich C, Kuehbacher A, Dimmeler S (2008) Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovascular Research 79: 581–588. doi: 10.1093/cvr/cvn156
